Healthcare / Drug Manufacturers - Specialty & GenericKSE
$4720.00
-135.00 (-2.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $10.3B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$465.7B
P/E
31.1x
↑EV/EBITDA
23.7x
↑ROE
3.7%
↑Gross Margin
45.8%
↓Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
-3.6%
FCF margin
5.1%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $200.71B · net income $12.56B · FCF $10.27B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $200.71B | $200.71B | $160.09B | $125.93B | $190.91B |
| Net Income | $12.56B | $12.56B | $-2.64B | $-31.33B | $-2.47B |
| EBITDA | $15.77B | $15.77B | $7.63B | $-31.47B | $5.84B |
| EPS | 152.00 | 152.00 | -35.81 | -420.52 | -33.05 |
| Gross Margin | 45.8% | 45.8% | 46.4% | 37.4% | 41.6% |
| Operating Margin | 7.1% | 7.1% | 1.0% | -29.8% | -0.1% |
| Net Margin | 6.3% | 6.3% | -1.6% | -24.9% | -1.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.33 | 0.35 | 0.00 |
| Current Ratio | 2.55 | 2.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $10.27B | $10.27B | $31.75B | $-12.20B | $11.47B |
| Returns | |||||
| ROE | 3.7% | 3.7% | -1.1% | -13.8% | -0.9% |
| Valuation | |||||
| P/E | 31.05 | 31.05 | — | — | — |
| EV/EBITDA | 23.72 | 23.72 | 44.59 | — | 101.60 |
| P/B | 1.14 | 1.14 | 1.44 | 2.17 | 2.58 |
| Growth & Yield | |||||
| Revenue Growth | 25.4% | 25.4% | 27.1% | -34.0% | — |
| EPS Growth | 524.5% | 524.5% | 91.5% | -1172.2% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
40.2%
EPS terminal req.
$418.82
Spread vs growth
484.3%
5Y implied EPS CAGR
27.2%
EPS terminal req.
$506.77
Spread vs growth
497.2%
10Y implied EPS CAGR
18.3%
EPS terminal req.
$816.16
Spread vs growth
506.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-35.81 → 152.00
Residual
+17.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.